EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma

Jessica Gates iD, Faizan Haris iD, Francesca Cefaloni iD, Paniz Khooshemehri, Linda Green, Mariana Fernandes, Louise Thomson, Cris Roxas, Jodie Lam, Grainne d'Ancona, Alexandra M Nanzer, Jaideep Dhariwal und 1 weitere

Allergy · 2025-06 · 80 (6) · 1669-1676

DOI: 10.1111/all.16590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 14.05.2025. Verfasst von Jessica Gates und 12 weiteren Autor:innen. Beteiligte Einrichtung: Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust, London, UK. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tezepelumab is an anti‐TSLP monoclonal antibody approved for the treatment of severe asthma. It has broad downstream anti‐T2 effects, offering the prospect of biological remission. Real‐world data on clinical remission rates with tezepelumab is lacking, and the relationship between clinical and biological remission is unclear. Finally, the effectiveness of tezepelumab in patients who have failed to respond to existing biologic therapies is unknown.

Methods

Clinical and biomarker data from adults with severe asthma treated with tezepelumab in a real‐world setting was analyzed. Clinical outcome measures including clinical remission were recorded along with rates of biological remission (defined as blood eosinophil count < 300 cells/mcL and FeNO < 25 ppb).

Results

One hundred seventy‐five patients were included. 98/175 (56%) had switched from another biologic. Following tezepelumab initiation, the exacerbation rate decreased from 3.1 (2.5) to 0.8 (1.4), with 59% of patients remaining exacerbation‐free at 1 year. 54% achieved an ACQ score < 1.5. Clinical remission at 1 year was observed in 36%, with a rate of 55% in T2‐high patients versus 19% in T2 low patients. The clinical response in biologic‐naïve and biologic switch patients was similar. FeNO declined from 41 ppb (24–76) to 24 ppb (16–38) and BEC fell from 300 cells/μL (60–610) to 180 cells/μL (105–320) (both p < 0.001). 38% achieved biological remission. 15% attained both clinical and biological remission.

Conclusion

Tezepelumab led to substantial clinical improvements and clinical remission in up to 55% of T2‐high patients with severe asthma. A disconnect between clinical and biological remission was observed. The long‐term significance of residual T2 inflammation on tezepelumab is unknown.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsHumansMaleFemaleMiddle AgedAdultTreatment OutcomeSeverity of Illness IndexRemission InductionBiomarkersAged

Stichwörter der Autor:innen

asthmaasthma treatmentbiologics

Substanzen

Antibodies, Monoclonal, HumanizedAnti-Asthmatic AgentstezepelumabBiomarkers

Autor:innen und Institutionen

  • Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust, London, UK.
  • School of Immunology and Microbial Sciences, King's College London, London, UK.

ORCID-Profile: Jessica Gates, Faizan Haris, Francesca Cefaloni, David J Jackson

Zitieren

APA

Gates, J., Haris, F., Cefaloni, F., Khooshemehri, P., Green, L., Fernandes, M., Thomson, L., Roxas, C., Lam, J., d'Ancona, G., Nanzer, A. M., Dhariwal, J., & Jackson, D. J. (2025). Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma. Allergy, 80(6), 1669-1676. https://doi.org/10.1111/all.16590

Vancouver

Gates J, Haris F, Cefaloni F, Khooshemehri P, Green L, Fernandes M, et al. Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma. Allergy. 2025;80(6):1669-1676. doi:10.1111/all.16590

BibTeX
@article{Gates2025,
  author = {Gates, Jessica and Haris, Faizan and Cefaloni, Francesca and Khooshemehri, Paniz and Green, Linda and Fernandes, Mariana and Thomson, Louise and Roxas, Cris and Lam, Jodie and d'Ancona, Grainne and Nanzer, Alexandra M and Dhariwal, Jaideep and Jackson, David J},
  title = {Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma},
  journal = {Allergy},
  year = {2025},
  volume = {80},
  number = {6},
  pages = {1669--1676},
  doi = {10.1111/all.16590}
}
Kostenlos starten →